Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Nanjing Youzhiyuan Pharmaceutical Technology Co., Ltd., established on 2016-08-17, Business scope includes biomedical technology research and development,Technical Services;Class I medical device sales;Environmental Protection Technical Services;Instrumentation,Self-operated and agent import and export business of various domestic commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Class III medical device business;Production of Class II Medical Devices;Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class II Medical Devices;Sales of plastic products;Sales of technical glass products;Sales of daily glass products;Instrument Repair;Office Supplies Sales;Hardware retail;Communication equipment sales;electronics sales;Sales of bio-based materials;Pharmaceutical special equipment sales;Fermentation process optimization technology research and development;Biochemical product technology research and development;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.

Shenzhen Teled Medical Co., Ltd., established on 2014-04-21, Business scope includes general business items:Engaged in the research and development of medical devices;Operating import and export business,Technology development in the field of medical devices,technical consulting;Technology development of biotechnology products;Domestic Trade;medical research and development,The licensing program is:Engaged in the production and sales of medical devices and in vitro diagnostic reagents

Shenzhen Aima Biotechnology Co., Ltd. is a Chinese company located in Shanghai that produces biopharmaceutical products. It was founded in 2021 by Xia Meng and Chen Yu Zhang. Xia Meng has been the CEO since that date.

Beijing Huaanfo Pharmaceutical Research Center Co., Ltd., established on 2003-01-29, Business scope includes pharmacogenomics,predictive medicine,Cancer Genomics,Technology development of new drugs,technology transfer,technical consulting.(Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments.)

Nanjing Qizhen Genetic Engineering Co., Ltd., established on 2018-05-10, Business scope includes gene technology,Biotechnology,medical technology,Technological Development of Agricultural Technology,technical consulting,technology transfer,Technical Services;Biological Products Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)